Resmed Inc (RMD) is slightly undervalued and Solventum Corp (SOLV) is overvalued.
Against our estimates of intrinsic value, RMD trades at the wider discount: a margin of safety of +7%, against -73% for SOLV.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $239.56; the price of $221.97 is 7% below that value, and 76% of that value comes from beyond year five.
Leak Score 75/100 on 10 of 12 signals
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $51.30; the price of $88.75 is 73% above that value, and 79% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
| Metric | RMD | SOLV |
|---|---|---|
| Verdict | Slightly undervalued | Overvalued |
| Price | $221.97 | $88.75 |
| Intrinsic value | $239.56 | $51.30 |
| Margin of safety | +7% | -73% |
| Leak Score | 75/100 (10/12) | 59/100 (3/12) |
| Market cap | $32.0B | $15.1B |
| Revenue growth, 5 years | 12.1% | 0.5% |
| Operating margin | 34.0% | 8.5% |
| Net margin | 26.9% | 17.3% |
| Return on equity | 24.3% | 34.0% |
| Debt to equity | 0.13 | 1.10 |
| P/E | 21.3x | 10.8x |
| Forward P/E | 16.7x | 12.1x |
| P/B | 4.9x | 3.1x |
| Dividend yield | 1.2% | — |